Bill Hausdorff | Lead, Meningococcal Vaccine Development and Vaccines Public Health Value Proposition and
PATH, Center for Vaccine Innovation and Access

Trained as a biochemist at the Johns Hopkins University, the US National Institutes of Health and Duke University, Bill Hausdorff’s vaccine career started at the US Agency for International Development and Centers for Disease Control in Washington DC and Cairo, Egypt, where he worked to catalyze introduction of new vaccines into developing country immunization programs.

Bill subsequently spent 2 decades at two vaccine companies, first at Wyeth Vaccines in Rochester NY in the Scientific Affairs & Research Strategy group, and then at GlaxoSmithKline Vaccines in Wavre, Belgium where he served as Director of Epidemiology and later Vaccine Development Leader for pneumococcal conjugate vaccines. For the past 7 years he has been based at the international health NGO PATH in Washington DC, and is currently Lead, Meningococcal Vaccine Development and Vaccine Value Propositions. He is also Professor in the Faculty of Medicine, Université Libre de Bruxelles, Belgium.

Bill is author of over 100 scientific articles, including a recent review in Lancet Global Health on the need for and challenges to combination vaccine development and use. He serves on WHO’s Product Development Vaccine Advisory Committee (PDVAC).

Appearances:

Pre-Congress Workshops - Monday 30th March @ 10:00

Antimicrobial Resistance Workshop

Workshop Chair: Dr Christian Harding, CSO and Co-Founder, Omniose

10.00 Chair’s Opening Remarks
10:10 Keynote Intro – Impact of Vaccines on AMR *Topic TBC
10.30 Advancing Immunity: Clinical Development of a Peptide Conjugate Vaccine for Group A Streptococcus
10.45 Leveraging Serological Insights to Combat Emerging Pathogens and Antimicrobial Resistance
11.00 Selecting the Right Platform to Combat AMR
11.15 Creative Approaches to Licensure
11.30 De-risking Early Vaccine Development: Insights from CHIM, NHP Studies, and Correlates of Protection
11.45 Identifying Correlates of Protection
12:00 Combining approaches to Maximize Impact: P. aeruginosa Vaccine
12.15 Panel Discussion: Perceptions of AMR Vaccine Development in the Current Global Climate
14:00 – 15:00 Funding Pipeline Updates
- 14:00 Gates Foundation
- 14:15 CARB-X
- 14:30 TBC
- 14:45 TBC
15:00- 16:00 AMR Vaccines Development Updates
- 15:00 Shigella / Acinetobacter Vaccine Development *Title TBC
15:15 Universal Pneumococcal Vaccine Development *Title TBC
- Dr Tim Hirst, Chairman & CEO, GPN Vaccines
15:30 15:30 – 15:45 Stopping Superbugs: The Future of Anti-Bacterial Vaccine Development *Title TBC
15:45 15:45 – 16:00 Advancing a multivalent vaccine candidate to prevent S.aureus skin infections *Title TBC
16:00 Panel: Are Combination Vaccines the Way Forward for AMR /Defining the Value of Combo Vaccines
- Economic valuation of vaccines with reduction on AMR
- Improving coverage of viral vaccines which reduce AMR
- Explore the concept of Syndromic vaccines